Is administration of rituximab at 375 mg/m2 without splenectomy appropriate for ABO-incompatible renal transplant?

被引：17

作者：

Mitsuhata, N

Fujita, R

Ito, S

Mannami, M

Kojima, K

机构：

[1] Kure Kyosai Hosp, Dept Urol, Hiroshima, Japan

[2] Uwajima Tokushukai Hosp, Dept Urol, Uwajima, Japan

来源：

AMERICAN JOURNAL OF TRANSPLANTATION | 2005年 / 5卷 / 12期

关键词：

D O I：

10.1111/j.1600-6143.2005.01088.x

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

引用

页码：3019 / 3019

页数：1

共 5 条

[1] Delayed-onset neutropenia associated with rituximab therapy [J].

Chaiwatanatorn, K ;

Lee, N ;

Grigg, A ;

Filshie, R ;

Firkin, F .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 121 (06) :913-918

[2] The mechanisms of action of rituximab in the elimination of tumor cells [J].

Johnson, P ;

Glennie, M .

SEMINARS IN ONCOLOGY, 2003, 30 (01) :3-8

[3] Improved outcomes after ABO-incompatible living-donor kidney transplantation after 4 weeks of treatment with mycophenolate mofetil [J].

Mannami, M ;

Mitsuhata, N .

TRANSPLANTATION, 2005, 79 (12) :1756-1758

[4] Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy [J].

Sonnenday, CJ ;

Warren, DS ;

Cooper, M ;

Samaniego, M ;

Haas, M ;

King, KE ;

Shirey, RS ;

Simpkins, CE ;

Montgomery, RA .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (08) :1315-1322

[5] Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics [J].

Vieira, CA ;

Agarwal, A ;

Book, BK ;

Sidner, RA ;

Bearden, CM ;

Gebel, HM ;

Roggero, AL ;

Fineberg, NS ;

Taber, T ;

Kraus, MA ;

Pescovitz, MD .

TRANSPLANTATION, 2004, 77 (04) :542-548

← 1 →